Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.
Quiz|Articles|September 6, 2026
Dermatology Times Spot Test: September 6, 2026
Author(s)Marie Bosslett, Assistant Editor
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Welcome to Dermatology Times' Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology. This week, we’ll focus on the latest news in
Do you have a set of quiz questions to share? Contact editor Marie Bosslett at
Which mechanism characterizes oral TYK2 inhibitors such as envudeucitinib, socrodeucitinib, and zasocitinib?
What PASI 100 rate did envudeucitinib achieve among continuously treated patients at 48 weeks in the ONWARD3 long-term extension study?
Sonelokimab, evaluated in the phase 3 IZAR-1 trial, targets which cytokines?
Advertisement
Related to this article
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
By week 36, combination therapy altered 482 proteins and 467 genes vs 140 and 16 with ixekizumab alone in exploratory TOGETHER-PsO data.
Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases.
Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Intismeran Plus Pembrolizumab Improves RFS in Melanoma
3
Navigating New Treatments From Alopecia to Atopic Dermatitis
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5